- /
- Supported exchanges
- / US
- / GRF.AMEX
Eagle Capital Growth Fund Inc (GRF AMEX) stock market data APIs
Eagle Capital Growth Fund Inc Financial Data Overview
Eagle Capital Growth Fund, Inc. is a closed-end equity mutual fund launched and managed by Sims Capital Management LLC. The fund invests in the public equity markets of the United States. It makes its investments in the stocks of companies operating across diversified sectors. The fund benchmarks the performance of its portfolio against the S&P 500 Index. It was previously known as NAIC Growth Fund, Inc. Eagle Capital Growth Fund, Inc. was formed on April 11, 1989 and is domiciled in the United States.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Eagle Capital Growth Fund Inc data using free add-ons & libraries
Get Eagle Capital Growth Fund Inc Fundamental Data
Eagle Capital Growth Fund Inc Fundamental data includes:
- Net Revenue: 902 K
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Eagle Capital Growth Fund Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eagle Capital Growth Fund Inc News
New
Grifols (BME:GRF) Stock Still Looks Cheap Based On Current Earnings
Grifols has seen sharp swings over recent years, and that kind of ride naturally raises a blunt question for you as an investor: Does the current share price line up with what the business is actually...
Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings
Grifols has seen a long share price slide in recent years, which naturally puts the focus on one question for investors who still follow the stock. Is the current price tag properly supported by the e...
Grifols (BME:GRF) Starts Phase 3 Trials As Undervalued Narrative Faces A Fresh Test
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Grifols (BME:GRF) has started dosing patients in two Phas...
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Grifols, S.A. One trial, SIGMA, will evaluate Grifols' intravenous immunoglobulin (Ig) GAMUNEX®-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical tre...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.